J INTS BIO’s Novel Oral 4th Generation EGFR-TKI ‘JIN-A02’ effective against both cis and trans isomers of C797S mutations – ESMO 2022

On September 15, 2022 J INTS BIO reported the poster presentation of its novel, orally administered 4th generation EGFR-TKI ‘JIN-A02’ at the ESMO (Free ESMO Whitepaper) 2022, that showed high potency of JIN-A02 against both cis and trans isomers of C797S mutation (Press release, J INTS BIO, SEP 15, 2022, View Source;esmo-2022-301625927.html [SID1234619600]). This year’s edition of the European Society for Medical Oncology Congress (ESMO 2022) was held in Paris, France from 9th to 13th September.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Professor Cho, Byoung Chul, poster presentation of further preclinical data of its Novel Oral 4th Generation EGFR-TKI ‘JIN-A02’ at the 2022 European Society for Medical Oncology Congress in Paris, France (ESMO 2022)
Professor Cho, Byoung Chul, poster presentation of further preclinical data of its Novel Oral 4th Generation EGFR-TKI ‘JIN-A02’ at the 2022 European Society for Medical Oncology Congress in Paris, France (ESMO 2022)
Even though EGFR-TKI have improved treatment outcomes of patients with EGFR mutant NSCLC, resistance inevitably emerges with disease progression and often with CNS metastasis. C797S mutation is one of the most common on-target resistance mutation after the use of 3rd generation TKIs such as Osimertinib. ‘JIN-A02’ is a novel 4th generation EGFR-TKI, which is highly selective and potent against C797S double and triple mutations, with high BBB penetrance and intracranial efficacy.

The allelic context in which this C797S mutation is acquired, cis or trans isomers, have significant implications for treatment outcomes. This is especially so when C797S positive tumor are in cis form together with T790M mutation. In such situations, there are no available treatments.

J INTS BIO believes that JIN-A02 will be pivotal in the treatment of patients with EGFR mutant NSCLC harboring C797S double or triple mutations, regardless of allelic context. And the company is expecting the Phase I/IIa clinical study for JIN-A02 to start recruitment before the end of this year.